Patents by Inventor Lawrence M. Souza

Lawrence M. Souza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6716606
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor (“hpG-CSF”) which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: April 6, 2004
    Assignee: Amgen Inc.
    Inventor: Lawrence M. Souza
  • Publication number: 20030086936
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor (“hpG-CSF”) which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Application
    Filed: November 6, 2001
    Publication date: May 8, 2003
    Applicant: Amgen, Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 6379661
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor (“hpG-CSF”) which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: April 30, 2002
    Assignee: Amen Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 6004548
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: December 21, 1999
    Assignee: Amgen, Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 5830705
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: July 15, 1996
    Date of Patent: November 3, 1998
    Assignee: Amgen Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 5676941
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: October 14, 1997
    Assignee: Amgen Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 5582823
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: December 10, 1996
    Assignee: Amgen Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 5580755
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 3, 1996
    Assignee: Amgen Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 5356877
    Abstract: An analog of porcine growth hormone, is disclosed which retains the diabetogenic, insulin-sparing and lipolytic properties of porcine growth hormone while being capable of improving growth in mammals.
    Type: Grant
    Filed: June 22, 1993
    Date of Patent: October 18, 1994
    Assignees: Amgen, Inc., SmithKline Beckman Corporation
    Inventor: Lawrence M. Souza
  • Patent number: 5244882
    Abstract: An analog of porcine growth hormone, is disclosed which retains the diabetogenic, insulin-sparing and lipolytic properties of porcine growth hormone while being capable of improving growth in mammals.
    Type: Grant
    Filed: July 28, 1992
    Date of Patent: September 14, 1993
    Assignees: Amgen, Inc., SmithKline Beecham Corporation
    Inventor: Lawrence M. Souza
  • Patent number: 5151511
    Abstract: Novel polypeptides possessing biochemical and immunological properties of avian growth hormone are obtained by practice of recombinant DNA procedures. Novel DNA sequences are disclosed which are capable of directing the synthesis of such polypeptides in selected host microorganisms. In a preferred embodiment, a novel polypeptide with the properties of avian growth hormone of chicken species origins is produced as a result of bacterial expression of a novel plasmid, cGH-T21. This plasmid is harbored in transformed E. coli C600 cells deposited as A.T.C.C. 39182. Also disclosed is a DNA sequence capable of directing the synthesis of a novel polypeptide with the properties of avian growth hormone of turkey species origin.
    Type: Grant
    Filed: January 27, 1988
    Date of Patent: September 29, 1992
    Assignee: Amgen Inc.
    Inventors: Lawrence M. Souza, Thomas C. Boone
  • Patent number: 5104806
    Abstract: An analog of porcine growth hormone, is disclosed which retains the diabetogenic, insulin-sparing and lipolytic properties of porcine growth hormone while being capable of improving growth in mammals.
    Type: Grant
    Filed: March 12, 1987
    Date of Patent: April 14, 1992
    Assignees: Amgen, Inc., SmithKline Beecham Corporation
    Inventor: Lawrence M. Souza
  • Patent number: 4999291
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: March 6, 1989
    Date of Patent: March 12, 1991
    Assignee: Amgen Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 4918162
    Abstract: Methods and compositions are provided for identifying patients suffering from cancer, particularly neural and neuroendocrine cancers. It has been found that the protein expression product of the human N-mcy proto-oncogene may be detected in certain biological specimens, particularly tissue specimens and sputum samples. By obtaining immunogenic N-myc polypeptides, either synthetically or by isolation from a natural source, antibodies specific for the N-myc protein are obtained. Those antibodies may then be used in immunological techniques for detecting the presence of N-myc in the biological samples. In particular, the antibodies may be employed in immunohistochemical techniques to detect the N-myc protein in prepared tissue and sputum samples.
    Type: Grant
    Filed: October 5, 1988
    Date of Patent: April 17, 1990
    Assignee: The Regents of the University of California
    Inventors: Dennis J. Slamon, Lawrence M. Souza
  • Patent number: 4810643
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, i.e., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: March 3, 1986
    Date of Patent: March 7, 1989
    Assignee: Kirin- Amgen Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 4666839
    Abstract: Disclosed are methods for selective modification of double-stranded DNA sequences facilitating their storage and incorporation into expression vectors. Manufactured partially double-stranded DNA primers are hybridized to complementary regions of single-stranded forms of DNA sequences to be altered. Desired, selectively modified double-stranded DNA sequences are then formed by DNA polymerization and specific nuclease digestion of undesired double- and single-stranded regions. Illustratively provided are DNA sequences useful in the microbial expression of bovine prolactin and other valuable polypeptides such as avian growth hormone.
    Type: Grant
    Filed: December 1, 1982
    Date of Patent: May 19, 1987
    Assignee: Amgen
    Inventor: Lawrence M. Souza